← Leaderboards
Bingliang Fang
University Of Texas Md Anderson Can Ctr
$8,920,662
Attributed
$10,282,086
Total exposure
8
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.5M · FY2005–22$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
Funding mix
By agency
NIH$10,282,086 · 8
By mechanism
R01$7,550,619 · 4
U54$2,731,467 · 4
Top collaborators
- John V. Heymach5 shared
- Kathryn Ann Gold1 shared
Most similar at University Of Texas Md Anderson Can Ctr
Same institution · by research overlap
- Paul J Chiao$8,649,694
- Donghui Li$4,233,878
Others in their field
Top investigators on “Tumor”
- David Heimbrook · Leidos Biomedical Research, Inc.$636,492,067
- Leonard Freedman · Leidos Biomedical Research, Inc.$360,535,780
- Gregory H Reaman · National Childhood Cancer Foundation$208,276,509
- Richard K. Wilson · Washington University$203,917,615
- Norman Wolmark · Nsabp Foundation, Inc.$177,323,696
- Ronald T Mitsuyasu · University Of California Los Angeles$138,361,819
Research focus
TumorMalignant NeoplasmsPre-ClinicalResistanceNovel TherapeuticsCancer TherapyClinical TrialsMalignant Neoplasm Of LungCancer CellAnticancer ActivityCancer PatientApoptosisClinically RelevantMolecularPublic HealthBaseTherapeutic AgentsNormal CellGrowthNon-Small-Cell Lung CarcinomaMutationMutantReportingCancer Cell Line
Grant awards (33)
Research Project 1: PDX-based trials of precision medicine for treatment of KRAS mutant lung cancers$97,231
U54 · FY2022 · CA · contact PI
PDX Core$96,544
U54 · FY2022 · CA · contact PI
Research Project 1: PDX-based trials of precision medicine for treatment of KRAS mutant lung cancers$252,069
U54 · FY2021 · CA · contact PI
PDX Core$218,061
U54 · FY2021 · CA · contact PI
Research Project 1: PDX-based trials of precision medicine for treatment of KRAS mutant lung cancers$251,577
U54 · FY2020 · CA · contact PI
PDX Core$222,812
U54 · FY2020 · CA · contact PI
Overcoming Resistance to Anti-EGFR Therapy by Drug Repurposing$498,667
R01 · FY2019 · CA · contact PI
Research Project 1: PDX-based trials of precision medicine for treatment of KRAS mutant lung cancers$289,911
U54 · FY2019 · CA · contact PI
PDX Core$250,511
U54 · FY2019 · CA · contact PI
PDX Core$8,572
U54 · FY2019 · CA · contact PI
Research Project 1: PDX-based trials of precision medicine for treatment of KRAS mutant lung cancers$8,571
U54 · FY2019 · CA · contact PI
Overcoming Resistance to Anti-EGFR Therapy by Drug Repurposing$514,090
R01 · FY2018 · CA · contact PI
Research Project 1: PDX-based trials of precision medicine for treatment of KRAS mutant lung cancers$551,800
U54 · FY2017 · CA · contact PI
Overcoming Resistance to Anti-EGFR Therapy by Drug Repurposing$514,090
R01 · FY2017 · CA · contact PI
PDX Core$483,808
U54 · FY2017 · CA · contact PI
Overcoming Resistance to Anti-EGFR Therapy by Drug Repurposing$514,090
R01 · FY2016 · CA · contact PI
Overcoming Resistance to Anti-EGFR Therapy by Drug Repurposing$511,434
R01 · FY2015 · CA · contact PI
Novel CTD inhibitors with synthetic lethality to oncogenic Ras for cancer therapy$291,367
R01 · FY2013 · CA · contact PI
Novel CTD inhibitors with synthetic lethality to oncogenic Ras for cancer therapy$309,964
R01 · FY2012 · CA · contact PI
Novel CTD inhibitors with synthetic lethality to oncogenic Ras for cancer therapy$309,964
R01 · FY2011 · CA · contact PI
Oncolytic adenovector-mediated TRAIL gene therapy for cancers$305,116
R01 · FY2011 · CA · contact PI
Oncolytic adenovector-mediated TRAIL gene therapy for cancers$314,553
R01 · FY2010 · CA · contact PI
Novel CTD inhibitors with synthetic lethality to oncogenic Ras for cancer therapy$310,586
R01 · FY2010 · CA · contact PI
Oncolytic adenovector-mediated TRAIL gene therapy for cancers$314,553
R01 · FY2009 · CA · contact PI
Oncolytic adenovector-mediated TRAIL gene therapy for cancers$314,553
R01 · FY2008 · CA · contact PI
Oncolytic adenovector-mediated TRAIL gene therapy for cancers$303,964
R01 · FY2007 · CA · contact PI
Expression of Proapoptotic Genes for Cancer Therapy$328,079
R01 · FY2006 · CA · contact PI
Expression of Proapoptotic Genes for Cancer Therapy$335,975
R01 · FY2005 · CA
Expression of Proapoptotic Genes for Cancer Therapy$333,252
R01 · FY2004 · CA
Expression of the TRAIL Gene for Cancer Therapy$300,375
R01 · FY2004 · CA
Expression of Proapoptotic Genes for Cancer Therapy$330,982
R01 · FY2003 · CA
Expression of the TRAIL Gene for Cancer Therapy$298,150
R01 · FY2003 · CA
Expression of the TRAIL Gene for Cancer Therapy$296,815
R01 · FY2002 · CA